New drug for advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests an experimental drug called (R)-9b for men with a specific type of advanced prostate cancer that has stopped responding to hormone therapy. The goal is to see if this drug can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced prostate cancer that has spread to other parts of the body (like bones, lymph nodes, or organs).
- You have been on hormone therapy (like Lupron or Orgovyx) and your cancer is still growing despite this treatment.
- You have tried at least one newer hormone medication (like enzalutamide, abiraterone, or darolutamide) and it stopped working.
- You are well enough to go about your daily activities (ECOG 0 or 1) and your blood counts and organ function are in an acceptable range.
- You have not had a seizure disorder, and your heart function (measured by a test called QTcF) is normal.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (BMS-986460) for people with advanced prostate cancer that has stopped responding to hormone therapy. It aims to see if the drug can shrink or slow the cancer.
This trial tests a new drug, HRS-4357, against standard treatments for men with a specific type of advanced prostate cancer that has spread and no longer responds to hormone therapy. It aims to see if the new drug works better.
This study tests an experimental drug for men whose prostate cancer has spread and stopped responding to standard hormone therapies. It may be an option if your PSA is rising despite treatment with drugs like enzalutamide or abiraterone.
This early-phase study tests whether REGN4336 is safe and how well it works, by itself or with REGN5678, in adults with advanced prostate cancer. It may help people whose cancer has continued to worsen despite standard prostate cancer medicines.
This trial tests a new radioactive drug designed to target and destroy prostate cancer cells. It is for men whose cancer has continued to grow despite hormone therapy and other treatments like enzalutamide or abiraterone.
This trial tests a new medicine (BMS-986365) against the doctor's choice of standard therapy for men with metastatic castration-resistant prostate cancer. It aims to see which treatment works better and is safer.
Hear when a new Metastatic Castration-Resistant Prostate Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.